This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the standard of care and/or the potential of Merck's efinopegdutide (MK-6024) in patients with NAFLD
Ticker(s): MRKWho's the expert?
Institution: Physician Affiliate Group of New York
- Board-certified academic gastroenterologist with over 25 years of clinical experience; received specialized training during my fellowship in GI motility disorders, of which gastroparesis is one that we saw frequently.
- Treats about 2-3 patients with gastroparesis/month; probably have 50-75 patients with the condition in my practice.
Interview GoalThis call will focus on the results from phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with NAFLD
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
